3rd CEE CEE Meeting on Viral Hepatitis and Co-infection with HIV_Program

Wednesday 27 September - Day 1

8:30 Registration and breakfast
9:00 Opening of the Meeting
Session 1: Epidemiology / access to treatment

Local situation in in Slovenia and Balkan Countries
Mojca Maticic, MD, PhDUniversity Medical Centre Ljubljana, Slovenia


Local situation in Ukraine
Olga Golubovska, MD - Bogomolets National medical University, Ukraine

9:30 Local situation in Russia
Vadim Rassokhin, MD  - First St. Petersburg State Medical University named Acad IP Pavlov, Russia
9:40 Local situation in Romania
Oana Sandulescu, MD, PhD - Carol Davila University of Medicine and Pharmacy, Romania
9:50 Local situation in Baltic Countries
Saulius Caplinskas, MD, PhD - Lithuanian Centre for Communicable Diseases and AIDS, Lithuania
10:00 Local situation in Georgia
Akaki Abutidze, MD, MPH - AIDS and Clinical Immunology Research Centre, Georgia
10:10Local situation in Czech and Slovak Republics
Viktor Aster, MD, PhD - Charles University, Czech Republic
10:20 Local situation in Turkey
Cihan Yurdaydin, MD, PhD - University of Ankara, Turkey
10:30Local situation in Poland
Andrzej Horban, MD, PhD - University of Warsaw, Poland
10:40 Local situation in Hungary
Béla Hunyady, MD - Somogy County Kaposi Mór Teaching Hospital, Hungary
10:50 Coffee Break
11:15 Hep-CORE study: management of HBV and HCV infections throughout Europe
Jeffrey Lazarus, PhD - Copenhagen University Hospital, Denmark
11:40 New testing strategies for HCV: how can we achieve the WHO targets?
Mario Poljak, MD, PhD - University of Ljubljana, Slovenia

Round table discussion: access to HepC treatment

Introduction to Access to hepC treatment in EECA
Liudmyla Maistat - Medicines Patent Pool, Switzerland

Key barriers to hepC treatment for PWIDs
Eberhard Schatz - Corellation Network, the Netherlands

Direct price negotiations
Natalia Kravchenko - Alliance for Public Health, Ukraine

Compulsory licensing and patent opposition
Sergey Golovin - Treatment Preparedness Coalition, Russia

MPP progress in VL
Liudmyla Maistat - Medicines Patent Pool, Switzerland

13:00Group picture
13:15Lunch break
14:00Industry-sponsored symposium
Session 2: Challenges in the management of HCV infected patients
15:00 Management of HCC in HCV -infected patients
Markus Peck-Radosavljevic, MD - Klinikum Klagenfurt am Wörthersee, Austria
15:30Clinical case: re-treatment of HCV DAA failure with 3-class resistance
Pavel Khaykin, MD - MainFachArzt, Germany
15:50 Discussion
16:00 Coffee break
Session 3: Epidemiology, clinical presentation and management of Hepatitis E virus
16:30Management of Hepatitis E virus
Heiner Wedemeyer, MD - Medical School Hannover, Germany
17:15Industry-sponsored symposium
18:15Welcome reception and poster viewing
19:00Networking dinner - pre-registration required

Thursday 28 September - Day 2

8:30 Industry-sponsored symposium
Session 4: Treatment challenges in HIV & HCV – special populations

Special challenges in curbing the HIV epidemic in Central/Eastern Europe
Miłosz Parczewski, MD, PhD - Pomeranian Medical University, Szczecin, Poland

Abstract - driven presentations:

10:00 Results of Hepatitis C virus (hcv) treatment program among people with hiv/hcv co-infection who inject drugs (PWID)
Mr. Sergii Filipovich
10:10 HIV infection outbreak among IDUs in Minsk
Prof. Vladimir Eremin


10:30Coffee break
Session 5: Abstract - driven presentations
11:00Real-world effectiveness of ledipasvir/sofosbuvir in hepatitis C virus genotype 1, 2 and 3 infection: single-center experience within Georgian hepatitis C elimination program
Prof. Tengiz Tsertsvadze
11:10 Clinical characteristics of patients seeking care for chronic HCV infection – results from the large observational study in Central and Eastern European region and Kazakhstan (MOSAIC Study)
Dr. Béla Hunyady
11:20Changes in demographic, epidemiological and virological characteristics of patients with chronic hepatitis B virus infection in Slovenia between 1997 and 2010
Dr. Nina Kmet Lunarcek
11:30 Prognostic factors for liver fibrosis regression following sustained virologic response in patients with hepatitis C treated with direct acting antivirals
Dr. Oana Sandulescu
11:40 Direct-acting antivirals Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir with or without Ribavirin in HCV genotype 1-infected treatment-naïve or treatment-experienced patients with or without cirrhosis: real-life experience in Lithuania and Latvia
Dr. Ligita Jancoriene
11:50 Discussion
Special session: Future directions of ARVs
12:00Virologist Perspective
Charles Boucher, MD, PhD - Erasmus University, the Netherlands
12:15Clinician Perspective
Jonathan Schapiro, MD - Sheba Medical Centre, Israel
12:30Pharmacologist Perspective
Saye Khoo, MD, PhD - University of Liverpool, United Kingdom


13:00Lunch break
Session 6 Future in Diagnostic & Therapeutic Approaches

Innovative diagnostics for HIV, HBV and HCV
Dan Otelea, MD, PhD - Nat. Institute for Inf. Diseases “Prof. Dr. Matei Bals”, Romania

14:15The challenges in hepatitis B vaccination
Pierre Van Damme, MD, PhD - University of Antwerpen, Belgium
15:00Closing remarks